RIBER : STRONG REVENUE GROWTH FOR THE FIRST QUARTER OF 2017

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
54
RIBER : STRONG REVENUE GROWTH FOR THE FIRST QUARTER OF 2017

STRONG REVENUE GROWTH FOR THE FIRST QUARTER OF 2017

  • Growth in the order book at end-March: +37%
  • Revenue growth target of at least 30% in 2017

Bezons, April 24, 2017 - 5:45 pm - RIBER, a global market leader for semiconductor industry equipment, is today reporting its revenues for the first quarter of 2017.

Business developments

At March 31 (€'000,000) 2017 2016 Change
Systems 0.9 0 NA
Services and accessories 1.0 1.0 -
Cells and sources 7.3 0.4 x 18
Total reported revenues 9.2 1.4 +537%

In the first quarter of 2017, RIBER generated revenues of €9.2 million, up from €1.4 million in the first quarter of 2016. Sales growth primarily reflects the high level of deliveries of cells and sources for the photovoltaic and screen industries during the quarter. Alongside this, one MBE research system was delivered, whereas no systems were billed in the first quarter of 2016. Sales of services and accessories are stable year-on-year.

At March 31, 2017, the breakdown of RIBER's revenues was as follows: Asia (75%), Europe (21%) and the United States (3%).

Order book developments and outlook

At March 31 (€'000,000) 2017 2016 Change
Systems order book 10.5 9.5 +11%
Services and accessories order book 4.5 2.4 +88%
Cells and sources order book 2.0 0.5 +300%
Total order book 17.0 12.4 +37%

The order book at March 31, 2017 is up 37% from March 31, 2016 to €17.0 million. This progress has been driven primarily by the dynamic development of the cells and sources business, combined with growth in the services and accessories business.

The systems order book, up 11% at March 31, 2017, comprises four production machines for delivery in 2017 (versus two in 2016) and three research systems for delivery in 2017 (versus five in 2016). This order book does not include the order for a research system in the US, announced on April 18.

Considering RIBER's good visibility, it is targeting full-year revenue growth of at least 30% for 2017 compared with 2016. The Executive Board also implemented the share buyback program authorized by the Combined General Meeting of 22 June 2016.

Next date:

  • June 23, 2017: General Meeting

About RIBER: Riber designs and produces molecular beam epitaxy (MBE) systems as well as evaporation sources and cells for the semiconductor industry. This high-tech equipment is essential for the manufacturing of compound semiconductor materials and new materials that are used in numerous consumer applications, from new information technologies to OLED flat screens and next-generation solar cells.

Riber recorded €16.5 million in revenues for 2016, with 91 employees at the end of 2016. The company is ISO9001 certified. Riber is listed on Euronext Paris (Compartment "C") and is part of the CAC Small, CAC Technology and CAC T. HARD. & EQ indices. Riber is eligible for SME share-based savings schemes.

ISIN: FR0000075954 - RIB Reuters: RIBE.PA Bloomberg: RIB: FP BPI France-approved innovative company www.riber.com

RIBER Guillaume de Bélair tel: +33 (0)1 39 96 65 00 invest@riber.com CALYPTUS  Cyril Combe tel: +33 (0)1 53 65 68 68 cyril.combe@calyptus.net
Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...1d721aba04

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 627

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 311

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 150

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 364

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 105

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 108

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 354

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 35

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 364

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

VIQ Solutions' Leadership Transition Marks New Era Ahead

Updated Category News Views 244

VIQ Solutions Marks a New Chapter with Leadership Changes VIQ Solutions Inc. is making noteworthy changes in its executive team that will undoubtedly shape the organization's path forward. The firm, known for being a global provider of AI-driven, secure digital voice and video capture technology, has announced the retirement of Susan Sumner, who has been a pivotal figure...

Continue Reading
Lucid Group's Fourth Quarter Success: Record Deliveries Ahead

Updated Category News Views 130

Lucid Group Inc Reports Strong Q4 Earnings Lucid Group Inc (NASDAQ: LCID) has revealed its fourth-quarter financial results, demonstrating a significant improvement in revenue and production metrics. The results were reported after the market closed on a recent Tuesday, showcasing the company's ongoing commitment to innovation in the electric vehicle sector. Revenue...

Continue Reading
Verily Sightline Collaborates with Bangor University in Europe

Updated Category News Views 149

Verily Partners with Bangor University for Wastewater Testing Verily, recognized for its precision health technology, is extending its wastewater surveillance program into Europe through a promising partnership with Bangor University. This collaboration aims to take advantage of the innovative wastewater-based public health programs at Bangor to enhance testing...

Continue Reading
Amaero's Strategic Supply Agreement Boosts U.S. Titanium Production

Updated Category News Views 213

Amaero Secures Strategic Long-Term Supply Agreement Significant Milestone in Domestic Supply Chain Development Amaero International Limited (ASX:3DA), a prominent U.S. manufacturer of high-quality titanium powders, has successfully signed a three-year Supply Agreement with The Perryman Company, a leader in titanium production. This agreement marks a pivotal moment in...

Continue Reading
NextPlat: Insights from Interim CEO on Future Directions

Updated Category News Views 132

NextPlat Corp's Interim CEO Update NextPlat Corp (NASDAQ: NXPL), a prominent player in the consumer products and services sector, recently issued a pivotal update from its interim CEO, David Phipps. This detailed letter serves as a roadmap to navigate the company’s future after the unexpected passing of its former CEO, Charles M. Fernandez. The focus is on leveraging...

Continue Reading